Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases

简中 ENG ESP

Sinovac
News
Products
Innovation
Quality
Investor
Career
Contact Us

Sinovac
News
Products
Innovation
Quality
- QMS System
- Quality Certification
Investor
Career
Contact Us

简中
ENG
ESP

Home
News
Press Releases

Press Releases

Yaer：

--All--

--All--

SINOVAC's Hepatitis A Vaccine Healive^® Approved in Lebanon
2023/01/12
Study Proves the Immunogenicity and Safety of Co-administration with SINOVAC's WHO Prequalified Varicella and Hepatitis A Vaccines to 1 Year Old
2023/01/06
SINOVAC Reports Unaudited First Half of 2022 Financial Results
2022/12/29
SINOVAC's COVID-19 Vaccine Obtains the Official Pharmaceutical Product Registration in Hong Kong
2022/12/21
SINOVAC's Hepatitis A Vaccine Healive^® Launched in Indonesia
2022/12/06
SINOVAC Quadrivalent Influenza Vaccine Authorized for Commercialization in the Dominican Republic
2022/11/29
WHO Extended the Use of SINOVAC COVID-19 Vaccine under EUL to Individuals Aged 3 Years and Above
2022/11/22
SINOVAC's EV71 Vaccine Inlive^® Approved in Indonesia
2022/11/18
SINOVAC Donates 100,000 Doses of Hepatitis A Vaccines to Pakistan
2022/11/09
SINOVAC Varicella Vaccine Prequalified by WHO
2022/11/04
SINOVAC to Showcase Products at CPHI Frankfurt
2022/10/28
SINOVAC-Sponsored Automated Complex for Vaccine Storage and Distribution is Delivered to the Egyptian
2022/10/21
SINOVAC Joins Hands with UdeA to Boost Biomedicine R&D in Colombia
2022/10/21
SINOVAC Quadrivalent Influenza Vaccine Is Authorized For Marketing Use in Bangladesh
2022/09/16
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
2022/09/06
SINOVAC COVID-19 Vaccine Approved for Use in Children 6 Months and Older in Chile
2022/08/25
Sinovac Beijing's QC Laboratory Accredited By CNAS
2022/08/20
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
2022/08/15
SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
2022/07/19
SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil
2022/07/14
SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China
2022/07/04
SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa
2022/06/25
SINOVAC Polio Vaccine Prequalified by WHO
2022/06/02
Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population
2022/05/26
SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine
2022/05/11
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
2022/04/30
China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial
2022/04/26
SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong
2022/04/17
Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave
2022/03/23
Chile Research: CoronaVac^® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old
2022/03/16
Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak
2022/03/16
Latest Real-World Data Show Two-shots of CoronaVac^® Provides 74.5% Protection Against COVID-19 For Children and Adolescents
2022/03/16
Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided
2022/03/04
CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony
2022/02/25
CUHK and SINOVAC join in hands in building P3 laboratory
2022/02/18
SINOVAC Reports Unaudited First Half of 2021 Financial Results
2021/12/31
SINOVAC CoronaVac® Shows Good Safety in Pregnant and Postpartum Women
2021/12/29
South Africa Phase III Clinical Study Shows SINOVAC CoronaVac® Safe for Children as Young as 6 Months
2021/12/29
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
2021/12/10
Instituto Butantan and SINOVAC will hold 'CoronaVac® Symposium' international event about efficacy and security of CoronaVac®
2021/11/29
The 2nd International Conference on the Latest Researches, Experience Sharing on SINOVAC's COVID-19 Vaccine Was Held
2021/11/26
SINOVAC COVID-19 Vaccine Authorized for Commercial Sale in Myanmar
2021/11/08
SINOVAC actively discusses COVID-19 Vaccine application and the industry development with other countries
2021/10/26
SINOVAC agrees to supply an additional 101,000 doses of COVID-19 vaccines (CoronaVac®) to meet demand for inactivated virus vaccines from Singapore residents
2021/09/15
New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
2021/09/09
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
2021/09/09
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
2021/08/10
SINOVAC Announces Positive Data on Booster Dose of CoronaVac®
2021/07/27
SINOVAC's CoronaVac® Used on Child and Adolescent Population in China, Good Antibody Levels Observed After Three Months Following Vaccination
2021/07/20
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
2021/07/19
Clarification Statement
2021/07/18
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
2021/07/13
The Lancet Inf. Dis. Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Year
2021/07/02
SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months
2021/06/12
World Health Organization Authorizes SINOVAC’s CoronaVac^® for Emergency Use
2021/06/02
EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated
2021/05/06
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
2021/04/24
Summary of Clinical Trial Data of Sinovac’s COVID-19 Vaccine (CoronaVac^®)
2021/04/03
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine
2021/04/02
Sinovac Amends Shareholder Rights Plan
2021/02/22
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
2021/02/08
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
2021/02/05
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China
2021/02/03
Clarification Statement
2021/01/31
Statement
2021/01/28
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
2020/12/09
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
2020/12/07
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
2020/12/07
Brazil's National Health Surveillance Agency Authorizes Resumption of the Phase III Clinical Trial of CoronaVac™
2020/11/11
A Clarification of Interruption in Phase III trial On COVID-19 Vaccine
2020/11/10
A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain
2020/10/13
Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan
2020/09/28
Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children
2020/09/23
Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
2020/09/22
Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers
2020/09/09
Sinovac Reports Unaudited Second Quarter 2020 Financial Results
2020/08/28
Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
2020/08/25
Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
2020/07/06
Sinovac Reports Unaudited First Quarter 2020 Financial Results
2020/06/30
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
2020/06/24
Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19
2020/06/13
Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III
2020/06/11
Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development
2020/05/22
Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital
2020/05/18
Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE
2020/05/06
Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
2020/04/30
Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19
2020/04/17
Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19
2020/04/14
Sinovac Amends Shareholder Rights Plan
2020/02/22
Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children
2019/12/27
Sinovac Reports Unaudited Third Quarter 2019 Financial Results
2019/11/15
Sinovac Reports Unaudited Second Quarter 2019 Financial Results
2019/08/15
Sinovac Reports Unaudited First Quarter 2019 Financial Results
2019/07/10
Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F
2019/04/29
Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the JID
2019/04/16
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
2019/04/13
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
2019/03/08
Sinovac Determines Trigger Event Occurred Under Rights Agreement
2019/02/22
Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting
2018/12/19
Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Bei
2018/12/13
Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Senior Management
2018/11/29
Sinovac Reports Unaudited First Half of 2018 Financial Results
2018/11/08
Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
2018/10/22
U.S. District Court in Massachusetts Denies 1Globe’s Motion for Preliminary Injunction to Enjoin Sinovac’s Issuance of Shares
2018/10/17
Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
2018/10/16
Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures
2018/10/10
SEC Concludes Investigation of Sinovac
2018/08/20
Sinovac Raises $86.73 Million Through Private Placement Transaction
2018/07/03
Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court
2018/06/26
Sinovac Biotech Relaunches Company Website
2018/06/11
Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results
2018/05/11
Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
2018/05/08
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
2018/04/30
Sinovac Temporarily Blocks Access to Its Websites
2018/04/30
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
2018/04/27
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
2018/04/27
Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department
2018/04/24
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
2018/04/19
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
2018/04/18
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
2018/03/27
Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties
2018/03/15
Sinovac Amends Shareholder Rights Plan
2018/03/07
Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity
2018/03/06
Sinovac Announces Re-Election of All Directors at Annual General Meeting
2018/03/06
Sinovac Provides Update on Going Private Transaction
2018/02/07
Sinovac Holds 2017 Annual General Meeting of Shareholders
2018/02/07
Sinovac Schedules 2017 Annual Meeting of Shareholders
2017/12/29
Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
2017/12/23
Sinovac Biotech Cures Nasdaq Filing Deficiency
2017/12/01
Sinovac Reports Unaudited First Half of 2017 Financial Results
2017/12/01
Sinovac Biotech Announces Update on Nasdaq Matters
2017/11/30
Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results
2017/11/23
Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel
2017/11/09
Sinovac Biotech Announces Receipt of DelistingDetermination Letter fromNasdaq
2017/11/04
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
2017/09/25
Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F
2017/08/14
Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction
2017/06/26
Sinovac Biotech Announces Receipt of NASDAQ Letter
2017/05/17
Sinovac Reports Announces Filing Extension for 2016 Annual Report
2017/05/01
Sinovac Amends Shareholder Rights Plan
2017/03/24
Sinovac Responds to Recent Report
2016/12/23
Sinovac Reports Unaudited Third Quarter 2016 Financial Results
2016/11/28
Sinovac to Host Conference Call to Report Third Quarter 2016 Unaudited Financial Results
2016/11/15
Sinovac Announces Results of 2016 Annual General Meeting of Shareholders
2016/11/07
Sinovac Product Pipeline News
2016/10/19
Sinovac Schedules 2016 Annual Meeting of Shareholders
2016/09/30
Sinovac Reports Unaudited Second Quarter 2016 Financial Results
2016/08/23
Sinovac to Host Conference Call to Report Second Quarter and 2016 Unaudited Financial Results
2016/08/15
Sinovac Reports Unaudited First Quarter 2016 Financial Results
2016/05/27
Sinovac to Host Conference Call to Report First Quarter of 2016 Unaudited Financial Results
2016/05/20
Sinovac Files 2015 Annual Report on Form 20-F
2016/04/26
Sinovac Special Committee Engages Financial and Legal Advisors
2016/04/14
Sinovac Reports Unaudited Fourth Quarter and Full Year 2015 Financial Results
2016/04/05
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2015 Unaudited Financial Results
2016/04/02
Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights
2016/03/28
Sinovac Announces Receipt of Competing Non-Binding “Going Private” Proposal
2016/02/04
Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee
2016/02/01
Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine
2016/01/28
Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine
2016/01/04
Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
2015/12/10
Sinovac Reports Unaudited Third Quarter Financial Results
2015/11/12
Sinovac to Participate in Morgan Stanley Asia Pacific Summit
2015/11/04
Sinovac to Host Conference Call to Report Third Quarter 2015 Unaudited Financial Results
2015/11/02
Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate
2015/10/26
Sinovac Receives Tender to Supply Seasonal Flu Vaccine in Beijing
2015/09/14
Sinovac to Participate in Morgan Stanley Global Healthcare Conference
2015/09/10
Sinovac Reports Unaudited Second Quarter Financial Results
2015/08/13
Sinovac Announces Results of 2015 Annual General Meeting of Shareholders
2015/08/11
Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results
2015/08/04
Sinovac Schedules 2015 Annual Meeting of Shareholders
2015/07/08
Sinovac Reports Unaudited First Quarter 2015 Financial Results
2015/05/15
Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities
2015/05/14
Sinovac to Participate in UBS Global Healthcare Conference
2015/05/12
Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results
2015/05/07
Sinovac Files 2014 Annual Report on Form 20-F
2015/04/29
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results
2015/04/20
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results
2015/04/10
Sinovac to Participate in China Medical and Healthcare Investment Conference
2015/03/18
Sinovac Provides Updates on Pipeline Vaccines
2015/03/17
Sinovac Reports Unaudited Third Quarter Financial Results
2014/11/15
Sinovac Reports Unaudited Third Quarter Financial Results
2014/11/15
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
2014/11/05
Sinovac to Participate in Jefferies 4th Annual Asia Summit
2014/10/21
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference
2014/09/05
Sinovac to Participate in Upcoming Investor Conferences
2014/09/02
Sinovac Announces Results of 2014 Annual General Meeting of Shareholders
2014/08/27
Sinovac Reports Unaudited Second Quarter Financial Results
2014/08/15
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2014/07/25
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
2014/07/23
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
2014/07/21
Sinovac Schedules 2014 Annual Meeting of Shareholders
2014/07/14
Sinovac Announces Favorable Reduction in Value Added Tax Rate
2014/06/25
Sinovac Reports Unaudited First Quarter 2014 Financial Results
2014/05/22
Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results
2014/05/12
Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV)
2014/04/28
Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
2014/04/24
Sinovac Files 2013 Annual Report on Form 20-F
2014/04/16
Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
2014/03/20
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
2014/03/12
Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
2014/02/27
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
2014/01/29
test
2014/01/22
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
2013/11/13
Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive® under Expanded Immunization Program
2013/11/07
Sinovac to Host Conference Call to Report Third Quarter 2013 Unaudited Financial Results
2013/11/04
Sinovac to participate in UBS Asia Healthcare CEO Summit in November 2013
2013/10/31
Sinovac Holds 2013 Annual General Meeting of Shareholders
2013/08/21
Sinovac Reports Unaudited Second Quarter 2013 Financial Results
2013/08/14
Sinovac to Host Conference Call to Report Second Quarter 2013 Unaudited Financial Results
2013/07/31
Sinovac Schedules 2013 Annual Meeting of Shareholders
2013/07/19
Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration
2013/05/30
Sinovac Reports Unaudited First Quarter 2013 Financial Results
2013/05/28
Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
2013/05/24
Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results
2013/05/17
SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR
2013/05/15
Sinovac Presents at the UBS Global Healthcare Conference in May 2013
2013/05/14
Sinovac Files Annual Report on Form 20-F
2013/04/30
Sinovac Reports Unaudited Fourth Quarter and Full Year 2012 Financial Results
2013/04/18
Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2013/04/18
Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine
2013/04/18
Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year Unaudited Financial Results
2013/04/02
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease
2013/03/14
Sinovac Reports Unaudited Third Quarter 2012 Financial Results
2012/11/15
Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
2012/10/29
Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive^® Under Expanded Immunization Program
2012/09/25
Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
2012/09/18
Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
2012/09/10
Sinovac Holds 2012 Annual General Meeting of Shareholders
2012/08/23
Sinovac Reports Unaudited Second Quarter 2012 Financial Results
2012/08/15
TTTT
2012/08/14
Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
2012/08/06
Sinovac Schedules 2012 Annual Meeting of Shareholders
2012/07/16
Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
2012/06/26
Sinovac to Present at 5th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
2012/06/18
Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial
2012/06/12
Sinovac Reports Unaudited First Quarter 2012 Financial Results
2012/05/15
Sinovac Names Danny Chung Chief Financial Officer
2012/05/15
Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2012/05/08
Sinovac Participates in Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong
2012/04/12
Sinovac Files Annual Report on Form 20-F
2012/04/12
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results
2012/03/29
Sinovac Announces Director Appointment
2012/03/29
Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
2012/03/29
Sinovac to Host Conference Call to Report Fourth Quarter 2011 Unaudited Financial Results
2012/03/22
Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement
2012/01/24
Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
2012/01/10
Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
2012/01/04
Sinovac Reports Unaudited Third Quarter 2011 Financial Results
2011/11/14
Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
2011/11/09
Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
2011/11/08
Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu(R) to Beijing Citizens
2011/10/17
Sinovac's Animal Rabies Vaccine RabEnd Receives Production License
2011/09/27
Sinovac Reports Unaudited Second Quarter 2011 Financial Results
2011/08/12
Sinovac Receives GMP Certificate in Mexico for Seasonal Flu Vaccine and Hepatitis A Vaccine
2011/08/11
Sinovac Announces Management Changes
2011/08/05
Sinovac to Host Conference Call to Report Second Quarter 2011 Unaudited Financial Results
2011/08/01
Sinovac Holds 2011 Annual Shareholders Meeting
2011/07/15
Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
2011/06/28
Sinovac to Present at 5th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
2011/06/19
Sinovac Schedules 2011 Annual Meeting of Shareholders
2011/06/08
Sinovac Appoints Kenneth Lee to Board of Directors
2011/05/31
Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
2011/05/25
Sinovac Reports Unaudited First Quarter 2011 Financial Results
2011/05/13
Sinovac Presents at Two Investor Conferences in May 2011
2011/05/10
Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
2011/05/04
Sinovac Files Annual Report on Form 20-F
2011/04/23
Sinovac Reports Fourth Quarter and Full Year 2010 Financial Results
2011/03/31
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
2011/03/28
Sinovac Participates in UBS Greater China Healthcare Corporate Day
2011/03/25
Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
2011/03/10
Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
2011/03/03
Sinovac Presents at Rodman & Renshaw Annual China Investment Conference
2011/03/01
Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV)
2011/01/31
Sinovac Participates in UBS Greater China Conference 2011
2011/01/31
Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
2011/01/06
Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine
2010/12/28
Sinovac Reports Unaudited Third Quarter 2010 Financial Results
2010/11/15
Sinovac to Host Conference Call to Report Third Quarter 2010 Unaudited Financial Results
2010/11/01
Sinovac Participates in Two Investor Conferences in November
2010/10/27
Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
2010/10/25
Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
2010/10/25
Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
2010/10/25
Sinovac Reports Unaudited Second Quarter 2010 Financial Results
2010/08/16
Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
2010/08/10
Sinovac Holds 2010 Annual Meeting of Shareholders
2010/07/15
Sinovac Schedules 2010 Annual Meeting of Shareholders
2010/06/18
Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
2010/06/01
Sinovac to Participate at 2010 Shanghai CPhI Exhibition
2010/05/28
Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
2010/05/24
Sinovac Reports Unaudited First Quarter 2010 Financial Results
2010/05/14
Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2010/05/07
Sinovac Submits Clinical Trial Application for Mumps Vaccine to SFDA
2010/05/06
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results
2010/04/06
Sinovac to Host Conference Call to Report 2009 Fourth Quarter Financial Results
2010/03/30
Sinovac Enters Exclusive Supply and Distribution Agreements with Parenteral Biotech Ltd. for India
2010/03/30
Sinovac to Present at Inaugural China Healthcare Investment Conference
2010/03/24
Sinovac Completes Acquisition Aimed at Expanding Production Capacity
2010/02/24
Sinovac Announces Closing of Common Share Offering
2010/02/03
Sinovac Announces Exercise of Over-Allotment Option
2010/02/02
Sinovac Announces Upsizing and Pricing of Common Share Offering
2010/01/28
Sinovac Announces Plan to Launch Offering of Common Shares
2010/01/21
Sinovac Announces Recent Developments
2010/01/21
/C O R R E C T I O N -- Sinovac Biotech Ltd.
2010/01/14
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
2010/01/13
Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
2009/12/28
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
2009/12/28
Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009
2009/12/22
Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
2009/12/02
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
2009/11/25
Sinovac Files Shelf Registration Statement
2009/11/18
Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
2009/11/18
Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive®
2009/11/16
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
2009/11/16
Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results
2009/11/11
Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market
2009/11/03
Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
2009/10/28
Sinovac Receives Certificate of Approval to Distribute PANFLU.1 (H1N1) in Mexico
2009/10/22
Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
2009/09/30
Sinovac to Present at 2009 UBS Global Life Sciences Conference
2009/09/16
Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
2009/09/08
Hong Kong Department of Health Visited Sinovac on R&D and Production of H1N1 vaccine
2009/09/08
Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
2009/09/04
Sinovac Obtains Production License for H1N1 Vaccine
2009/09/03
Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
2009/09/02
Sinovac’s H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
2009/09/01
Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
2009/08/31
Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials
2009/08/19
Sinovac Reports Unaudited Second Quarter 2009 Financial Results
2009/08/19
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
2009/08/12
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
2009/08/04
Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
2009/07/23
IP Biotech and Sinovac Enter Partnership Agreement
2009/07/09
Sinovac Schedules 2008 Annual General Meeting
2009/07/01
Sinovac Receives Revised Approvals for Panflu
2009/07/01
Sinovac Receives China's First Influenza A (H1N1) Vaccine Order
2009/06/19
Sinovac Begins the Production of Influenza A (H1N1) Vaccine
2009/06/10
China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
2009/06/03
Sinovac Reports Unaudited First Quarter 2009 Financial Results
2009/05/15
Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
2009/05/11
Sinovac Biotech Ltd. Files Annual Report on Form 20-F
2009/05/02
Sinovac Receives RMB 87 Million Purchase Order for Healive from China
2009/05/01
Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
2009/04/30
Beijing Mayor Visited Sinovac on Promoting Development of Biopharmaceutical Industry
2009/04/27
CORRECTION-- Sinovac Biotech Ltd.
2009/04/10
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
2009/04/09
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
2009/04/02
Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status
2009/03/10
Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
2009/03/03
Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
2009/01/26
Sinovac Announces that Government Investigation Rules Out Healive
2009/01/03
Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
2008/12/22
Sinovac Announces Share Repurchase Program
2008/12/03
Sinovac Releases Statement on Healive Vaccine Suspension
2008/12/03
Sinovac to Host Conference Call to Report Third Quarter 2008 Financial Results
2008/11/13
Sinovac Named to Deloitte Technology Fast 50 China
2008/11/04
Sinovac to Participate in Two Upcoming Investor Conferences
2008/10/30
Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating
2008/10/10
Sinovac to Present at the 2008 UBS Global Life Sciences Conference
2008/09/26
Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
2008/09/25
Sinovac Initiates Development of Vaccine Against Hand, Foot, and Mouth Disease
2008/09/23
Sinovac Biotech Increases Ownership Position in its Operating Subsidiary Sinovac Beijing
2008/09/22
Sinovac Biotech Holds 2007 Annual General Meeting
2008/09/19
Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
2008/09/16
Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
2008/09/11
Sinovac Adjourns Annual General Meeting
2008/09/04
Sinovac to Present at the Susquehanna Financial Group's Second Annual Beijing Management Summit Conference
2008/09/02
Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
2008/08/15
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
2008/08/12
Sinovac to Host Conference Call to Report Second Quarter 2008 Financial Results
2008/08/10
Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
2008/06/30
Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
2008/06/17
Sinovac Delivers 80,000 Doses of Bilive to Gansu Earthquake Disaster Area
2008/06/12
Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims
2008/05/28
Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims
2008/05/22
Sinovac Reports First Quarter 2008 Unaudited Financial Results
2008/05/16
Sinovac to Host Conference Call to Report First Quarter 2008 Financial Results
2008/05/16
Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
2008/05/08
Sinovac Biotech Holds Annual General Meeting
2008/04/10
Sinovac Receives SFDA's Approval for Pandemic Influenza H5N1 Vaccine
2008/04/02
Sinovac Published Annual Report 2007 (20-F)
2008/04/01
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
2008/03/31
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
2008/03/26
Sinovac Announces Adjournment of Annual General Meeting
2008/03/25
Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
2008/03/25
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
2008/02/20
Sinovac Closes $9.75 Million Private Placement
2008/02/04
Sinovac Announces $9.75 Million Private Placement
2008/01/24
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2007/12/26
Sinovac Requests Extension for Annual Shareholders Meeting
2007/12/14
Sinovac's Hepatitis A Vaccine Healive Selected by Beijing Centers For Diseases Control and Prevention
2007/12/14
Sinovac Reports Third Quarter 2007 Unaudited Financial Results
2007/12/12
Sinovac Files Form 6-K with SEC
2007/11/21
Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
2007/11/21
Sinovac Enters Purchase Agreement with Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine
2007/11/05
Sinovac to Present at 2007 UBS Global Life Sciences Conference
2007/09/21
Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2007/09/21
Sinovac Announces Postponement of Annual General Meeting
2007/09/21
Sinovac Reports First Half 2007 Financial Results
2007/08/16
Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
2007/08/15
Sinovac Schedules First Half 2007 Financial Results Date
2007/08/14
Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd.
2007/08/02
Sinovac Schedules Annual General Meeting
2007/08/01
Sinovac Receives Full Payment for Heping Wang's Obligations
2007/07/30
Sinovac Issues Corporate Update
2007/07/30
Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1)
2007/05/10
Sinovac to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
2007/05/10
Sinovac Reports 2006 Financial Results
2007/05/10
Sinovac Reports First Quarter 2007 Unaudited Sales
2007/05/10
Sinovac Schedules 2006 Financial Results Date
2007/04/10
Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine
2007/03/12
FIRST HUMAN CASE IN 2007 REPORTED
2007/03/02
Sinovac Files Registration Documents for Euvax-B(TM) with SFDA Loan Repayment Received from One Former Director
2007/02/09
Sinovac Schedules Investor Conference Call for February 6, 2007
2007/02/05
Sinovac Clarifies Position on Restructuring Involving Its Chinese Subsidiary
2007/02/02
Sinovac Reports Fourth Quarter 2006 Unaudited Sales and Provides Corporate Update for 2007
2007/01/17
Sinovac Issues Corporate Update
2006/11/29
Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel
2006/10/17
Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM)
2006/09/28
Sinovac Reports Semi-Annual Results
2006/09/13
Sinovac Announces Its Clinical Trial Results of a Pandemic Influenza (H5N1) Vaccine Are Published by The Lancet
2006/09/08
Preliminary Result of Phase I Clinical Trial Shows That Sinovac's Pandemic Influenza Vaccine (H5N1) has High Safety and Immunogenicity Profile
2006/08/29
Sinovac Biotech Ltd. Changes Its Contact for Investor Relations
2006/08/03
Ludlow Capital Adds Sinovac to China Small Cap Index
2006/07/20
Sinovac Reports Fiscal 2005 Results
2006/07/15
Sinovac Biotech Files Form 12b-25 with the U.S. Securities and Exchange Commission
2006/07/03
Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)
2006/04/11
Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce Distribution Agreement to Market Vaccines in the Peoples Republic of China
2006/03/14
Sinovac Biotech Ltd. to Hold Annual Meeting of Stockholders and Business Objectives for 2006
2006/02/28
Sinovac Receives Approval to Commence Human Clinical Trials for Pandemic Influenza Vaccine
2005/11/23
Sinovac Passes China’s Ministry of Science and Technology “Pandemic Influenza Vaccine R&D Project” Examination
2005/11/15
Sinovac Receives GMP Certification for its Seasonal Influenza Vaccine, AnFlu
2005/10/27
Sinovac to present at the UBS Global Life Sciences Conference and Announces Additional Funding
2005/09/21
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
2005/09/12
WHO Meeting Held to Review the Results of Sinovac SARS Vaccine Phase I Trial and Discuss Phase II Protocols
2005/09/12
China’s new Vaccine Distribution System, and its Impact on Sinovac Biotech Ltd.
2005/09/12
Sinovac Biotech Ltd. Announces First Sales of its Proprietary Combined Hepatitis A&B Vaccine, BiliveTM
2005/09/12
Sinovac Biotech Ltd. Retains Segue Ventures, LLC for Investor Relations and Public Relations
2005/09/12
SINOVAC BIOTECH LTD. REPORTS 2004 SALES GROWTH OF 127 %
2005/09/12
Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce their Letter of Intent for Collaboration in Global Marketing and Vaccine Supply
2005/09/12
SINOVAC BIOTECH LTD. ANNOUNCES THAT IT HAS LAUNCHED THE MARKETING OF ITSPROPRIETARY COMBINED HEPATITIS A&B VACCINE, BILIVE™
2005/09/12
SINOVAC BIOTECH LTD. ANOUNCES THAT IT HAS RECEIVED THE NEW DRUG CERTIFICATE FROM THE CHINESE GOVERNMENT FOR ITS SPLIT FLU VACCINE
2005/09/12
Sinovac Biotech Ltd.: Updates on its Avian Influenza Vaccine Development
2005/09/12
Sinovac Biotech Ltd. Announces Final Approval by the Chinese FDA (SFDA) for Bilive"TM", its Proprietary Combined Hepatitis A&B Vaccine
2005/09/12
SINOVAC BIOTECH LTD. LISTED ON HALTER USX CHINA INDEX
2005/09/12

Sinovac
Innovation
Quality
- QMS System
- Quality Certification
Career
Follow Us

Sinovac
Innovation
Quality
- QMS System
- Quality Certification
Career
Follow Us

© SINOVAC